There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …

Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …

Proteins are among the most common therapeutics for the treatment of diabetes,
autoimmune diseases, cancer, and metabolic diseases, among others. Despite their …

Abstract Background and Aims Filgotinib is a small molecule that selectively inhibits Janus
kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is …

Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional
intravenous route of administration, potentially offering notable advantages for both patients …

Abstract Background and Aims Despite intravenous (IV) vedolizumab being established for
treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of …

Background and objective Treatment burden refers to the overall impact of medical
treatments on a patient's well-being and daily life. Our objective is to evaluate the impact of …

Therapeutic proteins may first be developed as intravenous (iv) therapies with new
subcutaneous (sc) dosage forms being subsequently developed to provide an alternative …